NetWorth
LeaderPortfolio
Yiling
Wu Yiling
Rank #1770
CHINA•Healthcare•Pharmaceuticals

Wu Yiling

Net Worth
$2.313B
-0.17% (24h)
Wu Yiling, born in 1949, is a Chinese billionaire and the honorary chairman of Yiling Pharmaceutical. His wealth stems from his stake in the company, which was founded in 1992. With a background in both Western and Traditional Chinese Medicine (TCM), Wu transitioned from practicing TCM for 11 years to building a pharmaceutical empire. Yiling Pharmaceutical's flagship product, Lianhua Qingwen capsules, gained international recognition during the COVID-19 pandemic. Wu's career highlights a blend of clinical pragmatism and entrepreneurial drive, making him a prominent figure in China's healthcare industry. As of March 10, 2026, his net worth is estimated at $2.5 billion, derived primarily from his ownership in Yiling Pharmaceutical.

How to read Wu Yiling's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Wu Yiling, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.313B alongside global rank #1770, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (CHINA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Wu Yiling was born in 1949 in China. His early life was influenced by his family's medical background, as his father was a doctor. He earned medical degrees from Hebei Medical University and Nanjing University of Chinese Medicine, gaining expertise in both Western and traditional Chinese medicine.

Rise to Success

After practicing traditional Chinese medicine for 11 years, Wu founded Yiling Pharmaceutical in 1992. The company focused on developing medications based on TCM principles. A key product, Lianhua Qingwen capsules, gained international attention during the COVID-19 pandemic. The capsules were recommended by Chinese health experts for treating mild cases of the virus, which boosted the company's revenue and expanded its global reach.

Key Business Strategies

Yiling Pharmaceutical's success is rooted in a strategy combining traditional Chinese medicine with modern pharmaceutical standards. Wu's leadership style incorporates clinical pragmatism, prioritizing real-world efficacy in drug development. The company's focus on innovative R&D, with significant investments, has been a key element of its growth. Yiling Pharmaceutical has expanded its product portfolio to include modern traditional Chinese medicine, chemical pharmacy, and health care products.

Philanthropy

While specific details about Wu Yiling's philanthropy are limited, it's known that he is dedicated to charitable causes. During the COVID-19 pandemic, Yiling Pharmaceutical donated Lianhua Qingwen capsules to support medical efforts, both domestically and internationally.

Career Timeline

2020

Lianhua Qingwen Capsules Recognition

Lianhua Qingwen capsules gained international attention during the COVID-19 pandemic.

2011

Yiling Pharmaceutical IPO

Yiling Pharmaceutical went public on the Shenzhen Stock Exchange.

1992

Founded Yiling Pharmaceutical

Wu established Yiling Pharmaceutical, a company focused on traditional Chinese medicine.

Philanthropic Impact

Healthcare$7.9M

COVID-19 Relief

Donation of Lianhua Qingwen capsules to Shanghai and Wuhan during the COVID-19 pandemic.

Key Business Ventures & Holdings

CompanyStakeValue
Yiling Pharmaceutical——

Net Worth History

In-Depth Analysis

Early Life

Wu Yiling was born in 1949 in China. His early life was influenced by his family's medical background, as his father was a doctor. He earned medical degrees from Hebei Medical University and Nanjing University of Chinese Medicine, gaining expertise in both Western and traditional Chinese medicine.

Rise to Success

After practicing traditional Chinese medicine for 11 years, Wu founded Yiling Pharmaceutical in 1992. The company focused on developing medications based on TCM principles. A key product, Lianhua Qingwen capsules, gained international attention during the COVID-19 pandemic. The capsules were recommended by Chinese health experts for treating mild cases of the virus, which boosted the company's revenue and expanded its global reach.

Key Business Strategies

Yiling Pharmaceutical's success is rooted in a strategy combining traditional Chinese medicine with modern pharmaceutical standards. Wu's leadership style incorporates clinical pragmatism, prioritizing real-world efficacy in drug development. The company's focus on innovative R&D, with significant investments, has been a key element of its growth. Yiling Pharmaceutical has expanded its product portfolio to include modern traditional Chinese medicine, chemical pharmacy, and health care products.

Philanthropy

While specific details about Wu Yiling's philanthropy are limited, it's known that he is dedicated to charitable causes. During the COVID-19 pandemic, Yiling Pharmaceutical donated Lianhua Qingwen capsules to support medical efforts, both domestically and internationally.

Data Sources & Methodology

Figures for Wu Yiling are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom